The use of phytoestrogens to improve quality of life and to preserve health in women during the menopausal transition and postmenopause

1. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J. Clin. Endocrinol. Metab. 2012; 97(4): 1159-68. https://dx.doi.org/10.1210/jc.2011-3362.
2. Сметник В.П., ред. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста: Клинические рекомендации. Климактерий. 2014; 4: 32с. [Smetnik V.P., ed. Menopausal hormone therapy and preserving the health of mature women: Clinical recommendations. Climacterium. 2014; 4: 32p. (in Russian)].
3. Baber R.J., Panay N., Fenton A., IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/ 10.3109/13697137.2015.1129166.
4. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-53. https://dx.doi.org/ 10.1097/GME.0000000000000921.
5. Takahashi T.A., Johnson K.M. Menopause. Med. Clin. North Am. 2015; 99(3): 521-34. https://dx.doi.org/10.1016/j.mcna.2015.01.006.
6. Lobo R.A. Hormone-replacement therapy: current thinking. Nat. Rev. Endocrinol. 2017; 13(4): 220-31. https://dx.doi.org/10.1038/nrendo.2016.164.
7. Position Statement. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155-72. https://dx.doi.org/10.1097/GME.0000000000000546.
8. Tsai S.A., Stefanick M.L., Stafford R.S. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011; 18(4): 385-92. https://dx.doi.org/10.1097/gme.0b013e3181f43404.
9. Siow R.C., Mann G.E. Dietary isoflavones and vascular protection: activation of cellular antioxidant defenses by SERMs or hormesis? Mol. Aspects Med. 2010; 31(6): 468-77. https://dx.doi.org/10.1016/j.mam.2010.09.003.
10. Messina M. Soy foods, isoflavones, and the health of postmenopausal women. Am. J. Clin. Nutr. 2014; 100(Suppl. 1): 423S-30S. https://dx.doi.org/ 10.3945/ajcn.113.071464.
11. Chinigarzadeh A., Karim K., Muniandy S., Salleh N. Isoflavone genistein inhibits estrogen-induced chloride and bicarbonate secretory mechanisms in the uterus in rats. J. Biochem. Mol. Toxicol. 2017; 31(4). https://dx.doi.org/ 10.1002/jbt.21878.
12. Budhathoki S., Iwasaki M., Sawada N., Yamaji T., Shimazu T., Sasazuki S. et al. JPHC Study Group. Soy food and isoflavone intake and endometrial cancer risk: the Japan Public Health Center-based prospective study. BJOG. 2015; 122(3): 304-11. https://dx.doi.org/10.1111/1471-0528.12853.
13. Basu P., Maier C. Phytoestrogens and breast cancer: in vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomed. Pharmacother. 2018; 107: 1648-66. https://dx.doi.org/ 10.1016/j.biopha.2018.08.100.
14. Ледина А.В., Прилепская В.Н. Фитоэстрогены и изофлавоноиды сои в лечении климактерического синдрома. Фарматека. 2012; 12(245): 86-9. [Ledina A.V., Prilepskaya V.N. Phytoestrogens and soy isoflavones in the treatment of menopausal syndrome. Farmateka. 2012; 12(245): 86-9. (in Russian)].
15. Wei P., Liu M., Chen Y., Chen D.C. Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac. J. Trop. Med. 2012; 5(3): 243-8. https://dx.doi.org/10.1016/S1995-7645(12)60033-9.
16. Loibl S., Lintermans A., Dieudonné A.S., Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas. 2011; 68(2): 148-54. https://dx.doi.org/10.1016/j.maturitas.2010.11.013.
17. Patisaul H.B., Jefferson W. The pros and cons of phytoestrogens. Front. Neuroendocrinol. 2010; 31(4): 400-19. https://dx.doi.org/ 10.1016/j.yfrne.2010.03.003.
18. Grosso G., Bella F., Godos J., Sciacca S., DelRio D., Ray S. et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr. Rev. 2017; 75(6): 405-19. https://dx.doi.org/10.1093/nutrit/nux012.
19. Zhang X., Gao Y.T., Yang G., Cai Q., Xiang Y.B., Ji B.T. et al. Urinary isoflavonoids and risk of coronary heart disease. Int. J. Epidemiol. 2012; 41(5): 1367-75. https://dx.doi.org/10.1093/ije/dys130.
20. Benkhedda K., Boudrault C., Sinclair S.E., Marles R.J., Xiao C.W., Underhill L. Food Risk Analysis Communication. Issued by health Canada’s food directorate. Health Canada’s proposal to accept a health claim about soy products and cholesterol lowering. Int. Food Risk Anal. J. 2014; 4: 1-12.
21. Sathyapalan T., Aye M., Rigby A.S., Thatcher N.J., Dargham S.R., Kilpatrick E.S. et al. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutr. Metab. Cardiovasc. Dis. 2018; 28(7): 691-7. https://dx.doi.org/10.1016/j.numecd.2018.03.007.
22. Gencel V.B., Benjamin M., Bahou S.N., Khalil R.A. Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev. Med. Chem. 2012; 12(2): 149-74. https://dx.doi.org/10.2174/138955712798995020.
23. Taku K., Melby M.K., Kronenberg F., Kurzer M.S., Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012; 19(7): 776-90. https://dx.doi.org/ 10.1097/gme.0b013e3182410159.
24. Bolanos R., Del Castillo A., Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 2010; 17(3): 660-6.
25. Johnson A., Roberts L., Elkins G. Complementary and alternative medicine for menopause. J. Evid. Based Integr. Med. 2019; 24: 2515690X19829380. https://dx.doi.org/10.1177/2515690X19829380.
26. Irace C., Marini H., Bitto A., Altavilla D., Polito F., Adamo E.B. et al. Genistein and endothelial function in postmenopausal women with metabolic syndrome. Eur. J. Clin. Invest. 2013; 43(10): 1025-31. https://dx.doi.org/ 10.1111/eci.12139.
27. Squadrito F., Marini H., Bitto A., Altavilla D., Polito F., Adamo E.B. et al. Genistein in the metabolic syndrome: results of a randomized clinical trial. J. Clin. Endocrinol. Metab. 2013; 98(8): 3366-74. https://dx.doi.org/10.1210/jc.2013-1180.
28. Terzic M., Micic J., Dotlic J., Maricic S., Mihailovic T., Knezevic N. Impact of phytoestrogens on serum lipids in postmenopausal women. Geburtsh. Frauenheilkd. 2012; 72(6): 527-31. https://dx.doi.org/10.1055/s-0031-1298624.
29. Sathyapalan T., Aye M., Rigby A.S., Fraser W.D., Thatcher N.J., Kilpatrick E.S. et al. Soy reduces bone turnover markers in women during early menopause: a randomized controlled trial. J. Bone Miner. Res. 2017; 32(1): 157-64. https://dx.doi.org/10.1002/jbmr.2927.
30. Chen L.R., Ko N.Y., Chen K.H. Isoflavone supplements for menopausal women: a systematic review. Nutrients. 2019; 11(11): 2649. https://dx.doi.org/10.3390/nu11112649.
31. Hairi H.A., Shuid A.N., Ibrahim N., Jamal J.A., Mohamed N., Mohamed I.N. The effects and action mechanisms of phytoestrogens on vasomotor symptoms during menopausal transition: thermoregulatory mechanism. Curr. Drug Targets. 2019; 20(2): 192-200. https://dx.doi.org/ 10.2174/1389450118666170816123740.
32. Ganai A.A., Husain M. Genistein attenuates D-GalN induced liver fibrosis/chronic liver damage in rats by blocking the TGF-β/Smad signaling pathways. Chem. Biol. Interact. 2017; 261: 80-5. https://dx.doi.org/10.1016/j.cbi.2016.11.022.
33. Demiroren K., Dogan Y., Kocamaz H., Ozercan I.H., Ilhan S., Ustundag B. et al. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin. Res. Hepatol. Gastroenterol. 2014; 38(1): 63-72. https://dx.doi.org/10.1016/j.clinre.2013.08.014.
34. Kobayashi M., Egusa S., Fukuda M. Isoflavone and protein constituents of lactic acid-fermented soy milk combine to prevent dyslipidemia in rats fed a high cholesterol diet. Nutrients. 2014; 6(12): 5704-23. https://dx.doi.org/ 10.3390/nu6125704.
35. Schmidt M., Arjomand-Wölkart K., Birkhäuser M.H., Genazzani A.R., Gruber D.M., Huber J. et al. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. Gynecol. Endocrinol. 2016; 32(6): 427-30. https://dx.doi.org/ 10.3109/09513590.2016.1152240.
36. Громова О.А., Торшин И.Ю., Лиманова О.А., Никонов А.А. Патофизиология вегетативно-сосудистых пароксизмов (приливы) у женщин в период менопаузы и механизм действия β-аланина. Новая клинико-фармакологическая концепция. Гинекология. 2010; 12(2): 29-36. [Gromova O.A., Torshin I.Yu., Limanova O.A., Nikonov A.A. Pathophysiology of vegetative-vascular paroxysms (tides) in menopausal women and the mechanism of action of β-alanine. New clinical and pharmacological concept. Gynecology. 2010; 12(2): 29-36. (in Russian)].
37. Jacobsen J.P.R., Oh A., Bangle R., Roberts W.L., Royer E.L., Modesto N. et al. Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. Neuropsychopharmacology. 2019; 44(12): 2082-90. https://dx.doi.org/10.1038/s41386-019-0400-1.
38. Freedman R.R. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas, 2010; 65(4): 383-5. https://dx.doi.org/10.1016/j.maturitas.2009.11.025.
39. Froese D.S., Fowler B., Baumgartner M.R. Vitamin B12, folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation. J. Inherit. Metab. Dis. 2019; 42(4): 673-85. https://dx.doi.org/10.1002/jimd.12009.
40. Gregory J.F., Park Y., Lamers Y., Bandyopadhyay N., Chi Y.Y., Lee K. et al. Metabolomic analysis reveals extended metabolic consequences of marginal vitamin B-6 deficiency in healthy human subjects. PLoS One. 2013; 8(6): e63544. https://dx.doi.org/10.1371/journal.pone.0063544.
41. Ganguly P., Alam S.F. Role of homocysteine in the development of cardiovascular disease. Nutr. J. 2015; 14: 6. https://dx.doi.org/10.1186/1475-2891-14-6.
42. Anavi S., Tirosh O. iNOS as a metabolic enzyme under stress conditions. Free Radic. Biol. Med. 2020; 146: 16-35. https://dx.doi.org/10.1016/j.freeradbiomed.2019.10.411.
43. Fisher M.J. Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke. 2013; 44(11): 3275-85. https://dx.doi.org/10.1161/STROKEAHA.113.000736.
44. Siti H.N., Kamisah Y., Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul. Pharmacol. 2015; 71: 40-56. https://dx.doi.org/10.1016/j.vph.2015.03.005.
45. Saito M., Marumo K. The effects of homocysteine on the skeleton. Curr. Osteoporos, Rep. 2018; 16(5): 554-60. https://dx.doi.org/10.1007/s11914-018-0469-1.
46. Raszewski G., Loroch M., Owoc A., Łukawski K., Filip R., Bojar I. Homocysteine and cognitive disorders of postmenopausal women measured by a battery of computer tests-central nervous system vital signs. Arch. Womens Ment. Health. 2015; 18(4): 623-30. https://dx.doi.org/10.1007/s00737-015-0518-z.
47. Di Meco A., Li J.G., Praticò D. Dissecting the role of 5-lipoxygenase in the homocysteine-induced Alzheimer's disease pathology. J. Alzheimers Dis. 2018; 62(3): 1337-44. https://dx.doi.org/10.3233/JAD-170700.
48. Banecka-Majkutewicz Z., Kadziński L., Grabowski M., Bloch S., Kaźmierkiewicz R., Jakóbkiewicz-Banecka J. et al. Evidence for interactions between homocysteine and genistein: insights into stroke risk and potential treatment. Metab. Brain Dis. 2017; 32(6): 1855-60. https://dx.doi.org/10.1007/s11011-017-0078-1.
49. Jenks B.H., Iwashita S., Nakagawa Y., Ragland K., Lee J., Carson W.H. et al. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. J. Womens Health (Larchmt). 2012; 21(6): 674-82. https://dx.doi.org/10.1089/jwh.2011.3153.

Received 25.09.2020

Accepted 06.10.2020